Preprint Article Version 1 NOT YET PEER-REVIEWED

Immunization with E Plus NS1-2a Enhanced Protection against Dengue Virus Serotype 2 in Mice

  1. Department of Microbiology, School of Basic Medical Sciences, Capital Medical University, Beijing, 100069, China
Version 1 : Received: 1 December 2016 / Approved: 1 December 2016 / Online: 1 December 2016 (10:37:10 CET)

How to cite: Wu, Y.; Fang, S.; Cui, X.; Gao, N.; Fan, D.; An, J. Immunization with E Plus NS1-2a Enhanced Protection against Dengue Virus Serotype 2 in Mice. Preprints 2016, 2016120006 (doi: 10.20944/preprints201612.0006.v1). Wu, Y.; Fang, S.; Cui, X.; Gao, N.; Fan, D.; An, J. Immunization with E Plus NS1-2a Enhanced Protection against Dengue Virus Serotype 2 in Mice. Preprints 2016, 2016120006 (doi: 10.20944/preprints201612.0006.v1).

Abstract

Dengue virus (DENV), the causative agent of dengue fever (DF), is one of the most important mosquito-borne viruses that can infect humans. Although much effort has been made on prevention and control of dengue, there are currently no anti-viral drugs or worldwide approved vaccines yet. In this study, we immunized six-week-old Balb/c mice with DNA vaccine candidates E and NS1-2a of DENV serotype 2 or the combination of them (E+NS1-2a) via an electroporation (EP)-assisted intramuscular gene delivery system and evaluated the immune response and protection. The highest specific antibody titres and cytokine levels secreted by splenocytes as well as the highest survival rate were observed in the E+NS1-2a group, followed by E group and NS1-2a group. Our data suggested that the combination of E and NS1-2a delivered by EP may be a superior preventive strategy against DENV.

Subject Areas

Dengue virus; E; NS1-2a; electroporation; DNA vaccine

Readers' Comments and Ratings (0)

Discuss and rate this article
Views 31
Downloads 33
Comments 0
Metrics 0
Discuss and rate this article

×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.